Latest Breaking News On - Thoracic oncology group of australasia - Page 1 : comparemela.com
Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development
sydneysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sydneysun.com Daily Mail and Mail on Sunday newspapers.
Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development
australiannews.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from australiannews.net Daily Mail and Mail on Sunday newspapers.
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy.
DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in MPM with the combination of chemotherapy and durvalumab, and warrant confirmation in a randomized phase 3 trial.
E-Mail
IMAGE: Patrick Forde, MD, is the lead US investigator for the newly opened DREAM3R clinical trial, which is evaluating chemo-immunotherapy in patients with malignant pleural mesothelioma. view more
Credit: Johns Hopkins University
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy. DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype, said lead US investigator Patrick Forde, MD, of Johns Hopkins University. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in MPM with the combi